grit42 and its collaborator Fraunhofer are leading the way in the digital fight against AntiMicrobial Resistance
Today Fraunhofer and grit42 announced that their collaboration across multiple AntiMicrobial Resistance (AMR) projects - funded by the Innovative Medicines Initiative (IMI) - has made significant progress, setting up a FAIR data framework that can utilise knowledge graphs and prepares AMR data for potential machine learning.
Merry Christmas from grit42. And Slartibartfast.
We wish all of our customers, partners, family, friends, and designers of Norwegian fjords a very merry Christmas and a happy new year! Despite another year shadowed by the global pandemic, things are going quite well for grit42. We have welcomed new customers and partners in 2021, so really looking forward to continuing the positive […]
Contera Pharma selects grit42 for scientific data management
Today grit42 announces that its platform for scientific data management and analysis, has been selected by Contera Pharma, a biotech company developing innovative therapies to treat neurological disorders.
Merry Christmas from grit42. And Zaphod Beeblebrox.
We wish all of our customers, partners, family, friends, and depressed robots a very merry christmas and a happy new year!
ERA4TB, an international consortium to accelerate the development of comprehensive treatments against tuberculosis
The ERA4TB (European Regimen Accelerator for Tuberculosis) project is a public-private initiative dedicated to the development of drugs against tuberculosis. With a team of more than thirty organizations and a budget of over 200 million euros ERA4TB will focus on developing a new, improved tuberculosis treatment. The partners will share their expertise, knowledge and resources to rapidly progress new candidate drugs into clinical trials.
Merry Christmas from grit42. And Marvin.
We wish all of our customers, partners, family, friends, and depressed robots a very merry Christmas and a happy new year!
New IMI project “COMBINE” launched to accelerate the fight against antimicrobial resistance
11 European partners today announced that they are launching a new project, The Collaboration for Prevention and Treatment of Multi-Drug Resistant Bacterial Infections (COMBINE), under the IMI AMR Accelerator Programme. COMBINE will support projects in the AMR Accelerator with effective management, communication, and data capture capabilities, and carry out research to strengthen the scientific basis in the AMR field. COMBINE is funded by IMI, a joint initiative between the European Commission (EC) and the European Federation of Pharmaceutical Industries and Associations (EFPIA). COMBINE receives EUR 8 million from the EC; EFPIA in-kind contributions total EUR 17 million.
Strengthening our commitment to help tackle antimicrobial resistance, we’re joining the BEAM Alliance
Today, the digital laboratory specialists, grit42, joins the BEAM (Biotech companies in Europe combating AntiMicrobial Resistance) Alliance.
Fraunhofer and grit42 join forces in the global fight against antimicrobial resistance
Fraunhofer IME and grit42 are working together under the global umbrella of IMI’s AMR Accelerator. The combined efforts of Fraunhofer IME and grit42 is to facilitate a coherent and annotated data structure for the new IMI-backed project, Gram-Negative Antibacterials NOW (GNA NOW), which also focuses on AntiMicrobial Resistance (AMR).
The IMI-backed project ‘GNA NOW’ kicks off its battle against antimicrobial resistance
New partnership will advance three antibacterial programmes as part of the Innovative Medicines Initiative (IMI), a public-private European R&D consortium.